BOSTON (MarketWatch) -- U.S.-traded shares of Prima Biomed Ltd. (US:pbmd) jumped 16% to $6.96 early Tuesday. The Australian biotech group is expected to release interim Phase II clinical data for its cancer vaccine CVac in October. Prima Biomed has been testing CVac to see if it can prevent the recurrence of ovarian cancer in patients who are in remission after undergoing surgery and/or chemotherapy. Researchers will also be presenting data on the product at the biennial meeting of the International Gynecologic Cancer Society, to be held Oct. 13-16 in Vancouver. Shares of Prima BioMed have rocketed 98% over the last 30 days. The stock began trading on the Nasdaq market on April 16.